FASTER, PLEASE: Successful in vivo test of breakthrough Staphylococcus aureus vaccine. “One of the largest problems in clinical medicine is the growing prevalence of multidrug-resistant, disease-causing strains of Staphylococcus aureus. Penicillin resistance is now extremely common across a spectrum of staph strains, and although a few new antibiotic approaches show promise, the general availability of these new drugs still lies years in the future. . . . Recently, a collaborative of researchers from the Novartis Vaccines Research Center in Sienna, Italy and the University of Chicago have demonstrated a highly efficacious vaccine for epidemiologically relevant S. aureus strains that combines five conserved antigens known to play different roles in S. aureus pathogenesis.” Good.